Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.49 |
| ▸ | CDC25B | P30305 | 6/20 | 0.49 |
| ▸ | ACP1 | P24666 | 5/20 | 0.49 |
| ▸ | DUSP3 | P51452 | 3/20 | 0.49 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CDC25A | P30304 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4666751 | 0.85 | PTPN1 (0.47) | PTPN1CDC25BACP1DUSP3HPSE | |
| SCHEMBL4663314 | 0.84 | PTPN1 (0.44) | PTPN1CDC25BACP1DUSP3HPSE | |
| SCHEMBL4662972 | 0.81 | PTPN1 (0.43) | PTPN1CDC25BACP1DUSP3HPSE | |
| SCHEMBL4664973 | 0.79 | PTPN1 (0.47) | PTPN1CDC25BACP1DUSP3HPSE | |
| SCHEMBL4663032 | 0.78 | PTPN1 (0.40) | PTPN1CDC25BACP1DUSP3HPSE | |
| SCHEMBL4664810 | 0.78 | PTPN1 (0.46) | PTPN1CDC25BACP1DUSP3HPSE | |
| SCHEMBL16431478 | 0.77 | CDC25B (0.73) | PTPN1CDC25BACP1DUSP3HPSE | |
| SCHEMBL4664905 | 0.76 | PTPN1 (0.39) | PTPN1CDC25BACP1DUSP3HPSE | |
| SCHEMBL4664770 | 0.76 | PTPN1 (0.39) | PTPN1CDC25BACP1DUSP3HPSE | |
| SCHEMBL4663353 | 0.76 | DUSP3 (0.45) | PTPN1CDC25BACP1DUSP3HPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | GODEL THIERRY | 2008-06-05 | — | — | US | claimed |
| EP-1689729-A1 | TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE | F. Hoffmann-La Roche AG (CH) | 2006-08-16 | — | — | EP | claimed |
| WO-2005058857-A1 | TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | claimed |
| US-20050119329-A1 | Tetronic and tetramic acids | HOFFMANN-LA ROCHE INC. | 2005-06-02 | — | — | US | claimed |
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | GODEL THIERRY | 2008-06-05 | — | — | US | disclosed |
| EP-1689729-A1 | TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE | F. Hoffmann-La Roche AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005058857-A1 | TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | disclosed |
| US-20050119329-A1 | Tetronic and tetramic acids | HOFFMANN-LA ROCHE INC. | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132562-A1 | TETRONIC AND TETRAMIC ACIDS | BACE1, PSEN1, BACE2 | PTPN1 2489/4885CDC25B 3121/4885ACP1 2849/4885 |
| US-20050119329-A1 | Tetronic and tetramic acids | BACE1, PSEN1, BACE2 | PTPN1 2489/4885CDC25B 3121/4885ACP1 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.